Results 41 to 50 of about 22,928 (253)

Mandibular Osteonecrosis Associated with Antacid Therapy (Esomeprazole)

European Journal of Case Reports in Internal Medicine, 2019
Introduction: Osteonecrosis of the jaw has been consistently reported in the literature associated to the high-dose intravenous bisphosphonate therapy. However, osteonecrosis can also occur in patients who have other risk factors.
Simone Marconcini, Enrica Giammarinaro, Saverio Cosola, Anna Maria Genovesi, Ugo Covani   +4 more
doaj   +1 more source

The awareness and practice of dentists regarding medication-related osteonecrosis of the jaw and its prevention: a cross-sectional survey

BMC Oral Health, 2021
Background Accurate documentation of a patient’s prior medication use and awareness of side effects associated with anti-osteoporotic agents can assist dentists to prevent medication-related osteonecrosis of the jaw. I aimed to determine the awareness of
A. Lum Han
doaj   +1 more source

Drug assumption and awareness about adverse drug reactions. The right to know. The case of the bone-modyfing agents: a systematic review

Frontiers in Oral Health
IntroductionMedication-related osteonecrosis of the Jaw (MRONJ) is an adverse drug reaction that affects the mandible and maxilla of patients exposed to BMA and AA therapies, causing the progressive destruction and death of bone.
Rodolfo Mauceri, Rodolfo Mauceri, Sonia Arduini, Martina Coppini, Martina Coppini, Martina Coppini, Monica Bazzano, Isabel Trujillo, Giuseppina Campisi   +8 more
doaj   +1 more source

Alternative treatments for oral bisphosphonate-related osteonecrosis of the jaws: a pilot study comparing fibrin rich in growth factors and teriparatide [PDF]

, 2014
Objectives: The aim of this study is to describe and compare the evolution of recurrent bisphosphonate-related osteonecrosis of the jaws (BRONJ) in patients treated with plasma rich in growth factors or teriparatide.
Gallego, Lorena, García-Consuegra, L., Gómez Alonso, Carlos, Junquera Gutiérrez, Luis Manuel, Junquera, Sonsoles, Pelaz, A.   +5 more
core   +1 more source

Alendronate-Induced Osteonecrosis of the Jaw in an Elderly Female

International Journal of Gerontology, 2012
Background: In recent years, more and more evidence has demonstrated that a rare symptom, osteonecrosis of the jaw, may be associated with long-term use of bisphosphonates.
Bi-Wei Jan, Hui-Wen Liu, Hung Yu, Shen-Chuan Wang, Chung-Ji Liu   +4 more
doaj   +1 more source

Osteonecrosis of the jaws by intravenous bisphosphonates and osteoradionecrosis : a comparative study [PDF]

, 2009
Aims: We analyze the possible clinical differences between bone jaw exposed areas in ONJ (osteonecrosis of the jaws) and ORN (osteoradionecrosis). Patients and method: Group 1 was composed with 53 ONJ cases and group 2 with 20 ORN cases. In both groups
Bagán Sebastián, José Vicente, Carbonell Pastor, Enrique, Díaz Fernández, José María, Gavaldá Esteve, Carmen, Hernández Bazán, Sergio, Jiménez Soriano, Yolanda, Murillo Cortés, Judith, Poveda Roda, Rafael, Sanchís Bielsa, José María, Scully, Crispian   +9 more
core   +1 more source

Drug-induced osteonecrosis of the jaw: the state of the art

Reumatismo, 2017
Osteonecrosis of the jaw (ONJ) is a rare adverse event of antiresorptive drugs such as bisphosphonates (BP) and denosumab (DMAb). The diagnosis of ONJ is considered in cases where exposed bone in the maxillofacial region does not heal within 8 weeks in a
A. Fassio, F. Bertoldo, L. Idolazzi, O. Viapiana, M. Rossini, D. Gatti   +5 more
doaj   +1 more source

Dental treatment considerations in the chemotherapy patient [PDF]

, 2011
Cancer patients can suffer oral toxic effects secondary to antineoplastic therapy in the form of radiotherapy and/ or chemotherapy. This risk is conditioned by a range of factors, including the high cell turnover rate of the oral mucosa, the diversity ...
Chaveli López, Begonya, Gavaldá Esteve, Carmen, Sarrión Pérez, María Gracia   +2 more
core   +1 more source

Osteonecrosis of the Jaw After Bisphosphonates Treatment in Patients with Multiple Myeloma [PDF]

, 2015
Bone lytic lesion in Multiple myeloma are the most commonly presented symptoms which require treatment with bisphosphonates (BPs). BPs are providing supportive care, reducing the rate of skeletal morbidity but evidently not abolishing it, the criteria ...
Alan Archibald (45342), Aleksei Traspov (4453843), Alex Triantafyllidis (4453852), Bin Yang (103252), Christophe Knorr (4453837), DeodĂĄlia Dias (4453849), Gono Semiadi (2600656), Hendrik-Jan Megens (116285), Kesinee Gatphayak (4453840), Laura Iacolina (3249051), Lawrence Schook (131212), Leilei Cui (416135), Lusheng Huang (110011), Martien Groenen (3191614), Massimo Scandura (534340), Miguel Perez-Enciso (225658), Natalia Zinovieva (4453834), Olivier Hanotte (89422), Panoraia Alexandri (3245007), Pekka Uimari (463592), Peter Dovč (4453846), Richard Crooijmans (512752)   +21 more
core   +3 more sources

Utility of quantitative standardized uptake value from pre-operative bone SPECT/CT for predicting post-surgical MRONJ healing response

EJNMMI Research
Background Medication-related osteonecrosis of the jaw (MRONJ) is a challenging condition often associated with long-term use of anti-resorptive medications.
Jung-Hyun Park, Da-Mi Yoon, Hai-Jeon Yoon, Jin-Woo Kim   +3 more
doaj   +1 more source